Protagen AG successfully joined forces with Novartis to support Clinical Development of a Novel Compound in an Autoimmune Indication
Protagen CBO Georg Lautscham commented: "Our innovative SeroTag technology has proven on numerous occasions that it can monitor the immune-health status of patients, thereby allowing for the first time the systematic determination of response prediction and disease as well as patient stratification markers to select the most appropriate drug and therapy in autoimmune indications. This was evaluated in our collaboration with Novartis and we would like to thank Novartis' R&D team for the excellent, productive and collaborative relationship."
Headquartered in Dortmund Germany, Protagen specializes in Pharma development services and novel companion diagnostics, in the field of immuno-oncology and autoimmune disease.
Protagen uses its proprietary SeroTag biomarker discovery platform to identify valuable biomarkers that support Pharma development and its NavigAID products to personalize treatment with targeted therapies. With state-of-the-art bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen is expanding its own pipeline of critically informative biomarkers and collaborates with other organizations to commercialize valuable tools for better personalized treatment strategies for cancer and autoimmune disease patients.
For more information, please visit www.protagen.com